鲁抗医药(600789.SH)拟向控股股东等定增募资不超12亿元

智通财经12-20 19:48

智通财经APP讯，鲁抗医药(600789.SH)发披露向特定对象发行A股股票预案，发行对象为包括公司控股股东华鲁集团在内的不超过三十五名符合中国证监会、上交所规定条件的投资者，发行股票数量不超过2.7亿股(含本数)。其中，华鲁集团拟认购鲁抗医药本次向特定对象发行股票数量的23.81%，即认购股票数量不超过6420.14万股(含本数)。本次向特定对象发行股票的募集资金总额不超过12亿元(含本数)，扣除发行费用后拟用：高端制剂智能制造车间建设项目、生物农药基地建设项目、新药研发项目、补充流动资金。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492119684?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-20 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492119684","market":"hk","top_or_hot":-1,"title":"鲁抗医药(600789.SH)拟向控股股东等定增募资不超12亿元","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600789\">鲁抗医药</a>(600789.SH)发披露向特定对象发行A股股票预案，发行对象为包括公司控股股东华鲁集团在内的不超过三十五名符合中国证监会、上交所规定条件的投资者，发行股票数量不超过2.7亿股(含本数)。其中，华鲁集团拟认购鲁抗医药本次向特定对象发行股票数量的23.81%，即认购股票数量不超过6420.14万股(含本数)。本次向特定对象发行股票的募集资金总额不超过12亿元(含本数)，扣除发行费用后拟用：高端制剂<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>制造车间建设项目、生物农药基地建设项目、新药研发项目、补充流动资金。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>鲁抗医药(600789.SH)拟向控股股东等定增募资不超12亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n鲁抗医药(600789.SH)拟向控股股东等定增募资不超12亿元\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2024-12-20 19:48</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600789\">鲁抗医药</a>(600789.SH)发披露向特定对象发行A股股票预案，发行对象为包括公司控股股东华鲁集团在内的不超过三十五名符合中国证监会、上交所规定条件的投资者，发行股票数量不超过2.7亿股(含本数)。其中，华鲁集团拟认购鲁抗医药本次向特定对象发行股票数量的23.81%，即认购股票数量不超过6420.14万股(含本数)。本次向特定对象发行股票的募集资金总额不超过12亿元(含本数)，扣除发行费用后拟用：高端制剂<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>制造车间建设项目、生物农药基地建设项目、新药研发项目、补充流动资金。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1227921.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600789","symbol_name":"鲁抗医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1227921.html","article_id":"2492119684","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492119684","pubTimestamp":1734695281,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，鲁抗医药(600789.SH)发披露向特定对象发行A股股票预案，发行对象为包括公司控股股东华鲁集团在内的不超过三十五名符合中国证监会、上交所规定条件的投资者，发行股票数量不超过2.7亿股(含本数)。其中，华鲁集团拟认购鲁抗医药本次向特定对象发行股票数量的23.81%，即认购股票数量不超过6420.14万股(含本数)。本次向特定对象发行股票的募集资金总额不超过12亿元(含本数)，扣除发行费用后拟用：高端制剂智能制造车间建设项目、生物农药基地建设项目、新药研发项目、补充流动资金。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600789":"鲁抗医药","BK0046":"生物疫苗","BK0239":"医药制造","BK0168":"禽流感","BK0188":"融资融券"},"translate_title":"Lukang Pharmaceutical (600789. SH) plans to raise no more than 1.2 billion yuan from controlling shareholders and other private placements","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600789":1},"content_text":"智通财经APP讯，鲁抗医药(600789.SH)发披露向特定对象发行A股股票预案，发行对象为包括公司控股股东华鲁集团在内的不超过三十五名符合中国证监会、上交所规定条件的投资者，发行股票数量不超过2.7亿股(含本数)。其中，华鲁集团拟认购鲁抗医药本次向特定对象发行股票数量的23.81%，即认购股票数量不超过6420.14万股(含本数)。本次向特定对象发行股票的募集资金总额不超过12亿元(含本数)，扣除发行费用后拟用：高端制剂智能制造车间建设项目、生物农药基地建设项目、新药研发项目、补充流动资金。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492119684"}